![]() | Fourth European Congress ofPharmaceutical SciencesMilan, Italy, September 11-13, 1998 | ![]() |
---|
Scientific contributions are welcomed from anywhere in the world on any topics covered by the EUFEPS '98 Congress. All abstracts will be rapidly considered by the Scientific Programme Committee, which will allocate papers for oral or poster presentation. Please send Abstracts (original plus 3 photocopies) as hard copies. Please note that abstracts sent by fax or e-mail cannot be accepted, unless backed up by original hard copies sent by express mail. The deadline for submission of abstracts is April 20, 1998. Abstract Format Confirmation of receipt of the Abstract Letter of acceptance Late-breaking Abstracts Abstract Book New EUFEPS Awards The Segre Award in Pharmacokinetics/Pharmacodynamics will be presented for the first time at EUFEPS '98 in Milan. Further details can be found in the General Information section.
A. STRATEGIES AND TECHNOLOGIES IN DRUG DISCOVERY A1. New Processes in Drug Discovery A2. New Targets for Novel Drugs A3. Discovery and Development of Novel Natural Products A4. Site-Specific Drug Delivery A5. Vectors for Gene Therapy
B. STRATEGIES AND TECHNOLOGIES IN DRUG DEVELOPMENT B1. Dosage Form Design: Clinical Issues B2. Drug Delivery Systems B3. Powder Technology, Science of Materials and Engineering B4. Peptide and Protein Drugs B5. Parenteral Drug Development B6. Development of Generics B7. Biodisposition and Bioequivalence B8. Pharmacokinetics/Pharmacodynamics and Biotransformation in Drug Development B9. Cell and Tissue Culture in Pharmaceutical Development B10. Chemical Development: Current Issues B11. Advances in Analytical Technologies
C. STRATEGIES FOR SELECTIVITY IN DISEASE TREATMENT AND PREVENTION C1. Therapeutic and Pharmaceutical Advances in the Treatment of Chronic Diseases C2. Drugs and AIDS C3. Drugs and Alzheimer's Disease C4. Drugs and Atherosclerosis C5. Drugs and Cancer C6. Drugs and Neurodegenerative Diseases C7. Oxidative Damage and Radical Formation Antagonists
D. TRENDS IN DRUG RESEARCH D1. Biotechnology Drug Development and Characterization D2. New Vaccines D3. New Approaches Against Drug Resistance D4. Generics in the Global Pharmaceutical Market D5. Research and Regulatory Issues in Clinical Pharmacy
An abstract form is available as an Adobe Acrobat (PDF) file. You must either download the Adobe Acrobat PDF Viewer plug-in or Adobe Acrobat Reader in order to view this file. You can download the Acrobat Reader for free at the Adobe website. 1. White paper should be used with a box of the following dimensions: 115 mm wide x 155 mm high. Single space all typing on the form. Abstracts must be submitted in English. The text of the abstract should be a single paragraph starting with a 3-space indentation. Leave 1 space between last line of address(es) and first line of text. Leave no top or left margin within the box. Use short specific titles. Use standard abbreviations. Give the title in bold uppercase characters. Capitalize the first letter of trade names. Please type the abstract using a point size of preferably 11 or 12 (in any case not smaller than 10). Please type within the dimensions of the box as noted above. 2. Your abstract must include a concise, descriptive title, author(s), location where work was done, text and acknowledgments. 3. Your abstract should be of the informative type, containing: (a) a short statement of the study's specific objectives, unless this is given by the title; (b) a brief statement of methods, if pertinent; (c) a summary of the results obtained; (d) a statement of the conclusions. It is NOT acceptable to state: "The results will be discussed". 4. When using abbreviations for compounds, spell them out in full when first mentioned, followed by the abbreviation in parentheses (see sample abstract). Do not abbreviate compounds in the title of the abstract. 5. Spell out any Greek letter in the title. Avoid superscripts and subscripts in the title. Any hand-written symbols must be drawn in black ink. Tables are permitted within the abstract text. 6. Underline only the name of the author who will actually present the paper. Unless otherwise stated, it is assumed that the first named author will be the presenter. The presenting author will receive all future correspondence. 7. Please remember that your abstract will appear in a 70% reduced form in the Abstract Book exactly as you submit it. Any erasure smudges, errors, misspellings, poor hyphenations and deviations from good usage will be glaringly apparent in the published abstract. If a mistake is made in typing, type the corrected word on another sheet of paper and very carefully glue over the incorrect word with rubber cement. 8. The original typed copy of your abstract form (for reduced reproduction by photo-offset in the Abstract Book) must be submitted together with 3 photocopies. Abstracts sent by fax and by e-mail will NOT be accepted, unless the original is sent by express mail. 9. Please note: Resubmission of an abstract to make corrections or changes is not possible. 10. Any question concerning your abstract should be referred to the EUFEPS '98 Secretariat: EUFEPS '98
SAMPLE ABSTRACT TO SHOW STYLE
THE PHARMACOLOGY OF LEUKOTRIENE C4 IN ISOLATED GUINEA-PIG
LUNGS Leukotriene C4 (LTC-4) has been recently identified as an important component of slow reacting substance of anaphylaxis (SRS-A) and considerable work is now in progress to elucidate its physiological role. Since SRS-A has been known to play a major role in a number of immediate hypersensitivity reactions and in anaphylaxis, we decided to investigate the cardiopulmonary potential of LTC-4 with special attention to its capacity to trigger formation of other arachidonic acid (AA) metabolites................................
ABSTRACT FORM to be sent as hard copy by April 20, 1998 to: EUFEPS '98 |
|